Synergistic Induction of Oxidative and Endoplasmic Reticulum Stress by Tempol and ML210 Combination Therapy in B16F10
Ebru Çelik1, Percin Pazarci2, Ömer Kokaçya3
1Department of Dermatology, Siirt Training and Research Hospital, Siirt 56000, Türkiye.
Abstract:
Given the challenges in treating metastatic melanomas, there is a growing need for novel and effective therapeutic strategies. This study aimed to understand molecular mechanisms underlying synergistic effects of a Tempol and ML210 combination in B16F10 murine melanoma cells and to evaluate its therapeutic potential. We hypothesized that this combination would synergistically induce cell death by increasing oxidative stress and triggering ER stress. B16F10 melanoma cells were treated with Tempol and ML210 alone or in combination for 48 h. Cell viability was determined using MTT assay. Oxidative stress was evaluated by measuring Total Antioxidant Status (TAS), Total Oxidant Status (TOS), and intracellular H2O2 levels. Apoptotic markers (caspase-3, Bax, Bcl-2) and ER stress proteins (GRP78, GADD153, IRE1α, ATF6) were quantified by ELISA. Combination treatment significantly inhibited cell proliferation compared to monotherapies. Molecular analyses revealed that combination caused depletion of TAS and increase in TOS and intracellular H2O2 levels. Furthermore, combination treatment synergistically upregulated ER stress markers and pro-apoptotic proteins while significantly suppressing anti-apoptotic Bcl-2 expression. In conclusion, the combination of Tempol and ML210 synergistically induces cell death in B16F10 melanoma cells by disrupting redox balance and activating ER stress-mediated apoptosis. These findings suggest a potential strategy for melanoma treatment that warrants further in vivo investigation.
Insights
The combination of Tempol and ML210 synergistically kills melanoma cells by increasing oxidative stress and endoplasmic reticulum (ER) stress, offering a potential new therapy for metastatic melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Metastatic melanoma presents significant treatment challenges.
- Novel therapeutic strategies are urgently needed.
Purpose of the Study:
- Investigate the molecular mechanisms of Tempol and ML210 combination therapy in B16F10 melanoma cells.
- Evaluate the therapeutic potential of this combination by assessing its effects on oxidative stress, ER stress, and apoptosis.
Main Methods:
- B16F10 melanoma cells were treated with Tempol and ML210 alone or in combination.
- Cell viability was assessed using MTT assay.
- Oxidative stress markers (TAS, TOS, H2O2), apoptotic markers (caspase-3, Bax, Bcl-2), and ER stress proteins (GRP78, GADD153, IRE1α, ATF6) were quantified via ELISA.
Main Results:
- The combination treatment significantly inhibited melanoma cell proliferation compared to monotherapies.
- Combination therapy depleted Total Antioxidant Status (TAS), increased Total Oxidant Status (TOS) and intracellular H2O2 levels, indicating increased oxidative stress.
- Synergistic upregulation of ER stress markers and pro-apoptotic proteins (caspase-3, Bax) was observed, alongside significant suppression of anti-apoptotic Bcl-2 expression.
Conclusions:
- Tempol and ML210 combination synergistically induces cell death in melanoma cells.
- This effect is mediated by disruption of redox balance and activation of ER stress-induced apoptosis.
- The findings suggest a promising therapeutic strategy for melanoma that warrants further in vivo research.
